News | June 30, 2021
Aarey Drugs and Pharmaceuticals Q4FY21 PAT at Rs. 1.40 Cr
The company has reported total income of Rs.355.43 crores during FY 2020-21
The company has reported total income of Rs.355.43 crores during FY 2020-21
The company has posted net profit of Rs.12.12 crores for the 12 months period ended March 31, 2021
Fingolimod is an immunomodulating drug. It is a sphingosine 1-phosphate receptor modulator indicated for the treatment of relapsing forms of multiple sclerosis
The end user can validate the authenticity of the product by scanning the digital code with the help of a smartphone letting the end user know it is safe to use
The company is exploring all legal options to challenge the award.
The company recorded revenue of Rs 528crore as compared to Rs 444 crore, registering a growth of 19% over the corresponding quarter ended 31st March 2020
The company expects to see steady performance led by new launches and gradual normalization post the scale-up in vaccination
The company does not believe that the warning letter will have an impact on disruption of supplies or the existing revenues from operations of this facility
In an exclusive interview with Rahul Koul of Indian Chemical News, Priyanka Chigurupati, Executive Director, Granules Pharmaceuticals Inc. USA shared details about the company's performance, R&D initiatives, Capex plan, CSR, and future outlook. Excerpts of the interview:
The study was conducted in patients with mild to moderate COVID-19
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
